Single dose tocilizumab for COVID-19 associated cytokine storm syndrome: less is more.

Niels W Boone,Dirk Jan A R Moes,Sofia Ramiro,Remy L M Mostard,Cesar Magro-Checa,Christel M P van Dongen,Michiel Gronenschild,Eric van Haren,Jacqueline Buijs,Annick de Vries,Ralph Peeters,Robert B M Landewé,Dennis R Wong

British journal of clinical pharmacology（2023）

引用 0|浏览14

暂无评分

摘要

A single dose (8 mg/kg, max. 800 mg) is sufficient to cover a period of 16 days of IL-6 mediated hyperinflammation in COVID-19 induced CSS in MP treated patients. Based on bodyweight PK-simulations a fixed-dose tocilizumab of 400 mg should be considered to prevent overtreatment, future drug shortage and unnecessary drug expenses.

查看译文

关键词

COVID-19,cytokine storm syndrome,dose rationale,pharmacokinetics,tocilizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要